SCYNEXIS: SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

JERSEY CITY, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations of preclinical efficacy and pharmacokinetic data on its second-generation fungerp candidate SCY-247 at IDWeek 2024 taking place in Los Angeles, CA from October 16-19, 2024.Presentation details can be found below:Oral Presentation:Title:Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal InfectionsSession:Mycology Matters: Insights into Fungal InfectionsDate/Time:Thursday October 17, 2024 at 10:45 AM PDTLocation:Los Angeles Convention Center, Room 403 BPresenting author:David A. Angulo, M.D., President and CEO of SCYNEXISPoster Presentation:Title:SCY-247: A Second-generation IV/Oral Triterpenoid Antifungal with Extensive Tissue Distribution and Pharmacokinetics, and Low Drug-Drug Interaction PotentialSession:New Drug DevelopmentDate/Time:Friday October 18, 2024 at 12:15 - 1:30 PM PDTLocation: